Aspirin for primary prevention of cardiovascular disease in women

Area of Science:

• Cardiovascular disease prevention
• Pharmacological interventions
• Women's health

Background:

• Cardiovascular disease remains a leading cause of mortality.
• Primary prevention strategies are crucial for reducing cardiovascular events.
• The role of low-dose aspirin in primary prevention requires precise risk stratification.

Purpose of the Study:

• To define specific criteria for considering low-dose aspirin in primary cardiovascular prevention for women.
• To identify subgroups of women who may benefit from or be harmed by aspirin therapy.

Main Methods:

• Risk assessment models were used to estimate 10-year cardiovascular risk.
• Age, diabetes status, and calculated cardiovascular risk were key factors in the analysis.
• Benefit-risk assessment was performed to evaluate aspirin's utility.

Main Results:

• Low-dose aspirin is recommended for women aged 40-70 with a ≥20% 10-year cardiovascular risk.
• Consideration for aspirin is also advised for women with diabetes and a ≥10% 10-year cardiovascular risk.
• Bleeding risks outweigh benefits in low-risk women and those ≥70 years old.

Conclusions:

• Tailored aspirin therapy based on individual cardiovascular risk and age is essential.
• Risk stratification models are vital for optimizing primary prevention strategies.
• Careful consideration of bleeding complications is necessary when prescribing aspirin.